Sign In

Susan Dillon

President & CEO at Aro Biotherapeutics Company

Susan Dillon, also known as Sue Dillon, is a highly accomplished professional and a co-founder of Aro Biotherapeutics, focusing on innovative drug delivery solutions using the Centyrins protein platform for diseases with significant unmet medical needs. Prior to her current role, Sue held various leadership positions at Centocor and Janssen Research & Development, a division of Johnson & Johnson Pharmaceuticals, from 2001 to 2017. In 2009, she was appointed as the Global Therapeutic Area Head for immunology at Janssen, overseeing the drug discovery, biomarkers, translational medicine, and clinical development of several groundbreaking products for autoimmune disorders.

Susan Dillon
Add to my network

Location

Greater Philadelphia Area